Full-Time

Compliance Director

Amgen India

Posted on 2/21/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

No salary listed

Hyderabad, Telangana, India

In Person

Category
Legal & Compliance (1)
Required Skills
SAP Products
Risk Management
Requirements
  • Master’s degree and 14 to 16 years of Information Systems experience OR Bachelor’s degree and 16 to 18 years of Information Systems experience
  • Minimum of 12 or more years working in a corporate advisory or procedural support role with significant experience in operational controls for Global Capabilities Centers
  • Strong communications skills including English fluency
  • Experience in building compliance controls, processes, policies, and requirements with particular emphasis on anti-corruption, conflict of interest, compliance investigations, and corporate monitoring
Responsibilities
  • Support Amgen’s compliance leadership team in providing strategic advice pertaining to global compliance program framework.
  • Help develop global compliance capabilities out of Amgen India office (e.g., policy improvement, training governance, monitoring activities, investigation procedures).
  • Help develop and measure implementation strategies to develop and integrate the Amgen compliance program at Amgen India including; the Amgen compliance monitoring and auditing plans, develop and support robust compliance training program, provide support as needed for compliance investigations, interpret and apply Amgen compliance policies.
  • Support Amgen India mid and senior level leaders execute corporate compliance priorities.
  • Develop and maintain working knowledge of Amgen’s Global Compliance Policies and Standard Operating Procedures.
  • Develop and maintain working knowledge and understanding all applicable laws and codes regulating Amgen activities with government officials and the healthcare community (e.g., Prevention of Corruption Act, OPPI, UCPMP).
  • Access various Amgen source systems (e.g., SAP, Concur, C3) to gather information required to make assessments impacting our training and monitoring activities.
  • Co-chair compliance steering committee with Amgen India Managing Director focused on building compliance program controls and risk mitigation plans in response to: key compliance program metrics (e.g., investigations, monitoring, training), emerging business activities material to Amgen India, developments in external environment that have impact on compliance program.
  • Draft and deploy local compliance policies and procedures to address functional tactics / activities being carried out with members of the healthcare community and/or government officials that are incremental to our global compliance requirements (due to nuances in local regulations / codes).
  • Design and disseminate local compliance training modules and awareness messages designed to support executional alignment with Amgen policies and procedures.
  • Develop and support execution of local compliance monitoring framework based on outcomes emanating from compliance risk assessment.
  • Provide strategic compliance support on the following topics: interactions with government officials, protection of personal information, presence at external conferences, global commercial tactics with members of the healthcare community, conflicts of interest, confidential information, business conduct hotline, compliance culture / mindset and other code of conduct matters.
Desired Qualifications
  • Significant experience in developing compliance controls for Global Capabilities Centers in the biopharmaceutical industry
  • Experience in advising and counseling at the corporate executive level
  • Fluency in emerging areas of technology such as artificial intelligence, data analytics, and risk assessment tools

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Tarlatamab wins China NMPA approval May 2026 for $2B+ sales potential.
  • Q1 2026 revenues hit $8.6B with 16 brands posting double-digit growth.
  • Zai Lab partners on DLL3-ADC plus IMDELLTRA for SCLC trials.

What critics are saying

  • Prolia sales drop 34% to $727M from biosimilar competition in Q1 2026.
  • FDA warns Tavneos causes liver injuries, proposes approval withdrawal.
  • Horizon drugs Tepezza, Uplizna, Krystexxa underperform 19 months post-acquisition.

What makes Amgen unique

  • Amgen's BiTE platform establishes IMDELLTRA as second-line SCLC standard.
  • MariTide advances in Phase III obesity trials with monthly dosing.
  • UPLIZNA surges 73% post-IgG4 and gMG approvals in 2025.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Apr 10th, 2026
Amgen's lung cancer drug tarlatamab wins China approval, seen as $2B+ opportunity

Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.

Yahoo Finance
Apr 3rd, 2026
Amgen faces Tavneos liver injury warning as Zai Lab oncology collaboration expands IMDELLTRA pipeline

Amgen faces fresh safety concerns after the FDA warned of severe liver injuries, including vanishing bile duct syndrome, linked to Tavneos (avacopan) in late March 2026. The development adds regulatory risk to the company's investment profile. Separately, Zai Lab announced a global collaboration with Amgen to test its DLL3-targeting ADC alongside Amgen's IMDELLTRA in extensive-stage small cell lung cancer, underscoring the company's ongoing oncology expansion through external partnerships. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. However, pessimistic analysts model revenues slipping to $34.4 billion with earnings near $5.2 billion, reflecting concerns around pricing pressure, biosimilar competition and rising research and development spend alongside the new safety issues.

Yahoo Finance
Mar 30th, 2026
Amgen stock up 24% since Jim Cramer's June recommendation, beats earnings estimates

Amgen, one of the world's largest pharmaceutical companies, has seen its shares rise 24% since Jim Cramer discussed the stock on Mad Money in June 2025. The company is currently developing the weight loss drug MariTide. Amgen's shares jumped 7.5% in November 2025 after posting third-quarter results that beat analyst expectations, with $9.6 billion in revenue and $5.64 earnings per share against forecasts of $8.98 billion and $5.04 respectively. In February 2026, shares rose 8% following fourth-quarter earnings that also exceeded estimates. Cramer expressed cautious optimism about the biotech company, noting its mid-single-digit earnings growth and potential upside from its GLP-1 drug development. Whilst calling Eli Lilly his preferred GLP-1 play, Cramer said investors "could do a lot worse than Amgen" for a bargain option.

Yahoo Finance
Mar 25th, 2026
Wells Fargo lifts Amgen price target to $390, cites $20B myasthenia gravis market potential by 2036

Wells Fargo has raised its price target on Amgen to $390 from $375, maintaining an Equal Weight rating. The firm cited emerging therapies including CD20, BAFF/APRIL and next-generation complement inhibitors as potential drivers that could expand the generalized myasthenia gravis market threefold over the next decade, potentially reaching $15 billion in US sales and $20 billion globally by 2036. Separately, Jefferies initiated coverage on Amgen with a Hold rating and $350 price target on 10 March, noting the stock has gained approximately 35% over the past six months. Last month, Amgen reported fourth-quarter adjusted earnings per share of $5.29, beating the $4.76 consensus estimate, on revenue of $9.9 billion versus $9.45 billion expected.

Yahoo Finance
Mar 15th, 2026
Amgen joins TrumpRx discount scheme and lifts dividend to $2.52 per share

Amgen has announced a $2.52 per-share second-quarter dividend and joined the government-run TrumpRx platform to offer discounted drugs including Amjevita, Aimovig and Repatha. The company is also preparing for its 11 March presentation at the Leerink Global Healthcare Conference in Miami. The moves come alongside double-digit revenue and earnings per share growth in 2025 and advances in obesity and oncology programmes. However, the TrumpRx discounting could pressure net pricing as Amgen invests heavily in late-stage trials and manufacturing expansion. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. Some analysts see a tougher outlook, with revenue potentially drifting towards $34.4 billion and earnings around $5.2 billion.

INACTIVE